S
Stempeutics Research Pvt., Ltd.
Stempeutics Bangalore is a late-stage life science company focused on developing and commercializing novel therapeutics based on adult stem cells. It was ...
Country/Area ：India
Company Email ：hr@stempeutics.com
Industry ：BeautyBiotechnologyBusiness ServicesBusiness Services GeneralPersonal Care & Household CleaningMachinery
Company address ：NO.14 MANIPAL TOWERS AIRPORT ROAD HAL II STAGE BANGALORE 560008
Company website ：*****
Company phone ：+91 8025028101
Established ：2006
Company Revenue ：$16,533,000
Number of employees ：51-200
SIC Code ：87873
NAICS Code ：54541
Main Products ：PAF Stempeucel® Peri-anal Fistula In progress Phase I/II product for the treatment of Peri-anal Fistula due to Crohn's diseaseStempeutics receives Orphan Drug Designation (ODD) in the European Union for its novel stem cell drug “Stempeucel®” for the treatment of Thromboangiitis ObliteransHair Care Trichosera® A novel hair serum prepared from the bio-active medium of stem cells that promotes scalp hair growth and reduces hair fall (Commercially approved)Patents & CertificationsTherapeutics Range of ourTherapeuticsFacial Multisera Facial bundle Our strong pipeline in Bio-cosmetics which contains face wash, face scrub, day cream and night cream - derived from novel stem cell derived condition mediumDFU Stempeucel® Diabetic Foot Ulcer In progress Phase-III product for the treatment of non-healing Diabetic Foot UlcerCOVID-19 ARDSEye Care Perioptisera® An under-eye dark circle bioactive concentrate that reduces under-eye dark circles, eye bags and rehydrates & soothes the under-eye skin (Commercially approved)Image Stempeutics has signed a marketing agreement. with Alkem for distributing Knee Osteoarthritis product for India territorySkin Care Cutisera® A non-greasy intensive skincare translucent liquid that promotes a firm, well moisturized and clearer skin with reduced blemishes and fine lines (Commercially approved)OA Stempeucel® Knee Osteoarthritis First commercially approved Cell therapy product approved by the DCGI for the treatment of Knee Osteoarthritis (Commercially approved)CLI Stempeucel® Critical Limb Ischemia First commercially approved product by the DCGI for the treatment of Critical Limb Ischemia (Commercially approved)
Company News
Phase 3 Trial Results for Stempeutics Cell Therapy in Knee Osteoarthritis Published in American Journal of Sports Medicine (AJSM)
Aug 23, 2023
BENGALURU, India--(BUSINESS WIRE)-- #InflammatoryDiseases--Stempeutics announced the publication of the Knee OA Phase 3 trial results in the premier journal, the American Journal of Sports Medicine (AJSM).
Aug 23, 2023
Stempeutics gets DCGI nod for Phase 3 trial to treat Covid patientsJan 18, 2022
Stempeutics said it has received DCGI clearance to conduct Phase 3 clinical trial on its product for treating COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).
Jan 18, 2022Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)Aug 20, 2020
- First approved allogeneic cell therapy product globally for the treatment of CLI - Developed by Stempeutics over a period of twelve years, breakthrough treatment designed to address root cause of the disease at an affordable cost - Cipla to market and distribute the drug in India to provide patient access MUMBAI, India, Aug. 21, 2020 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its partner Stempeutics Research
Aug 20, 2020Business Info
CIN ：U73100KA2006PTC038256
Registered State ：Karnataka
Registrar Of Companies ：RoC-Bangalore
Category ：Company limited by Shares
Sub Category ：Non-govt company
Company Class ：Private
Company Status ：Active
Registered Office Address ：3RD FLOOR, #143, 212-215,EPIP INDUSTRIAL AREA HOODI VILLAGE,K.R.PURAM, HOBLI BENGALURU Bangalore KA IN 560066
Authorized Cap ：437000000.00
Paidup Capital ：418528470.00
Web Summary
Q1: What is the address of Stempeutics Research Pvt., Ltd.?
A1: The exact address of Stempeutics Research Pvt., Ltd. is not explicitly mentioned in the provided content, but it is mentioned that they are based in Bangalore.
Q2: What products does Stempeutics offer?
A2: Stempeutics offers a range of therapeutics and bio-cosmetics products, including Stempeucel for Critical Limb Ischemia, Knee Osteoarthritis, Diabetic Foot Ulcer, Peri-anal Fistula, Hair Care (Trichosera), Skin Care (Cutisera), Eye Care (Perioptisera), and a facial multisera bundle.
Q3: In which industry is Stempeutics primarily involved?
A3: Stempeutics is primarily involved in the life science industry, specifically in the development and commercialization of novel therapeutics based on adult stem cells.
Q4: What services does Stempeutics provide?
A4: While the provided content does not explicitly mention all services offered by Stempeutics, it mentions that they are committed to "Regenerating Hope" and nurturing cutting-edge research and clinical applications in cell therapy. They also offer a range of products and have partnerships with marketing companies for distributing their products.
Q5: What is the name of Stempeutics' flagship product?
A5: The name of Stempeutics' flagship product, Stempeucel, is mentioned as an on-demand, off-the-shelf product based on pooled, allogeneic Mesenchymal Stromal Cells derived from the bone marrow of healthy, adult volunteers.
Q6: What is the proprietary process used by Stempeutics to produce its products?
A6: According to the provided content, Stempeutics uses a proprietary, patented process to pool bone marrow-derived MSCs of healthy individuals, resulting in a product with strong immunomodulatory properties and broader cytokine/growth factors array.
Q7: What is the name of the marketing agreement signed by Stempeutics with Cipla?
A7: The name of the marketing agreement signed by Stempeutics with Cipla for distributing CLI (Critical Limb Ischemia) products in India territory is "Regenacip".
Q8: How many patents has Stempeutics filed across the globe?
A8: According to the provided content, scientists working at Stempeutics have filed over 100 patents across the globe, with 50+ patents already granted.
A1: The exact address of Stempeutics Research Pvt., Ltd. is not explicitly mentioned in the provided content, but it is mentioned that they are based in Bangalore.
Q2: What products does Stempeutics offer?
A2: Stempeutics offers a range of therapeutics and bio-cosmetics products, including Stempeucel for Critical Limb Ischemia, Knee Osteoarthritis, Diabetic Foot Ulcer, Peri-anal Fistula, Hair Care (Trichosera), Skin Care (Cutisera), Eye Care (Perioptisera), and a facial multisera bundle.
Q3: In which industry is Stempeutics primarily involved?
A3: Stempeutics is primarily involved in the life science industry, specifically in the development and commercialization of novel therapeutics based on adult stem cells.
Q4: What services does Stempeutics provide?
A4: While the provided content does not explicitly mention all services offered by Stempeutics, it mentions that they are committed to "Regenerating Hope" and nurturing cutting-edge research and clinical applications in cell therapy. They also offer a range of products and have partnerships with marketing companies for distributing their products.
Q5: What is the name of Stempeutics' flagship product?
A5: The name of Stempeutics' flagship product, Stempeucel, is mentioned as an on-demand, off-the-shelf product based on pooled, allogeneic Mesenchymal Stromal Cells derived from the bone marrow of healthy, adult volunteers.
Q6: What is the proprietary process used by Stempeutics to produce its products?
A6: According to the provided content, Stempeutics uses a proprietary, patented process to pool bone marrow-derived MSCs of healthy individuals, resulting in a product with strong immunomodulatory properties and broader cytokine/growth factors array.
Q7: What is the name of the marketing agreement signed by Stempeutics with Cipla?
A7: The name of the marketing agreement signed by Stempeutics with Cipla for distributing CLI (Critical Limb Ischemia) products in India territory is "Regenacip".
Q8: How many patents has Stempeutics filed across the globe?
A8: According to the provided content, scientists working at Stempeutics have filed over 100 patents across the globe, with 50+ patents already granted.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
